PHAT
NASDAQ HealthcarePhathom Pharmaceuticals, Inc. - Common Stock
Biotechnology
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
๐ Market Data
| Price | $9.28 |
|---|---|
| Volume | 1,136,184 |
| Market Cap | 750.76M |
| Beta | 0.500 |
| RSI (14-Day) | 27.1 Oversold |
| 200-Day MA | $12.43 |
| 50-Day MA | $10.45 |
| 52-Week High | $18.31 |
| 52-Week Low | $8.21 |
| Forward P/E | 8.36 |
| Price / Book | -2.16 |
๐ฏ Investment Strategy Scores
PHAT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (96/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PHAT in your text
Paste any article, transcript, or post โ the tool will extract PHAT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.